AVEO Oncology (AVEO) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
March 14, 2022 7:00 AM EDTTotal 2021 Net Revenue of $42.3 Million
FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021
FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescriptions Filled Compared to 3Q 2021
Full Year 2022 FOTIVDA U.S. Net Product Revenue Guidance of $100 to $110 Million
Long-term data from pivotal TIVO-3 study presented at ASCO GU 2022 continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA
... More